Speaker illustration

Doctor Massimiliano Camilli

Catholic University of the Sacred Heart, Rome (Italy)

Member of:

Heart Failure Association

Massimiliano Camilli is a cardiology Fellow at Catholic University of the sacred Heart in Rome. His interests are mostly related to Heart Failure, cardiovascular pharmacology and pathophysiology of Acute Coronary Syndromes.

Effects of sacubitril/valsartan on atrial function and structure as treatment response indicators in patients with heart failure with reduced ejection fraction: an observational prospective study.

Event: Heart Failure 2023

Topic: Imaging

Session: Chronic heart failure - imaging 1

Thumbnail

Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis.

Event: Heart Failure 2023

Topic: Cardiotoxicity of Drugs and Other Therapies

Session: ePosters in chronic heart failure - pathophysiology and mechanisms 2

Thumbnail

Effects of sacubitril/valsartan on atrial function and structure as treatment response indicators in patients with heart failure with reduced ejection fraction: an observational prospective study.

Event: EACVI 2023

Topic: Systolic and Diastolic Function

Session: Atrial Size and Function 2

Thumbnail

Advanced echocardiographic features, three-dimensional Left Ventricular-Arterial Coupling and vascular function in childhood cancer survivors exposed to anthracycline chemotherapy

Event: Heart Failure 2022

Topic: Cardio-Oncology

Session: Heart Failure ePosters - focus on Comorbidities and special population

Thumbnail

Long-term exposure to ambient air pollution portends a higher risk of coronary plaque vulnerability and instability in patients with acute coronary syndrome: an optical coherence tomography study.

Event: ESC Congress 2021 - The Digital Experience

Topic: Vulnerable Plaque

Session: Acute Coronary Syndromes ePosters

Thumbnail

Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis.

Event: Heart Failure 2021

Topic: Antidiabetic Pharmacotherapy

Session: ePoster session

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb